Results 31 to 40 of about 788,607 (367)

Factor Xa inhibitor for venous thromboembolism management in patient with cancer: a systematic review and meta-analysis [PDF]

, 2021
Background: An earlier systematic review reported no differences in the incidence of recurrent venous thromboembolism and major bleeding between factor Xa inhibitors and standard anticoagulation.
Farabi, Makhyan Jibril Al, Noor, Yoga Alfian, Putranto, Johanes Nugroho Eko, Siahaan, Pirhot Lambok Marnala Yosua, Wardhana, Ardyan Prima   +4 more
core   +1 more source

Anticoagulation by factor Xa inhibitors [PDF]

Journal of Thrombosis and Haemostasis, 2010
Therapeutic agents that regulate blood coagulation are critical to the management of thrombotic disorders, with the selective targeting of factor (F) Xa emerging as a promising approach.To assess anticoagulant strategies targeting FXa.A deterministic computational model of tissue factor (Tf)-initiated thrombin generation and two empirical experimental ...
Thomas Orfeo, Kathleen E. Brummel-Ziedins, Matthew Gissel, Kenneth G. Mann, Saulius Butenas   +4 more
openaire   +3 more sources

Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine-A Multicenter Trial [PDF]

, 2020
The rapid determination of the presence of direct oral anticoagulants (DOACs) in a patient remains a major challenge in emergency medicine and for rapid medical treatment decisions. All DOACs are excreted into urine.
Bauersachs, Rupert, Beyer-Westendorf, Jan, Crowther, Mark, Douxfils, Jonathan, Elalamy, Ismail, Harenberg, Job, Hetjens, Svetlana, Verhamme, Peter, Weiss, Christel   +8 more
core   +1 more source

Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a “CASPAR like” outcome from VOYAGER PAD

Clinical Cardiology, Volume 45, Issue 12, Page 1143-1146, December 2022., 2022
Abstract Background The Clopidogrel and Acetylsalicylic Acid in Bypass Surgery for Peripheral Arterial Disease (CASPAR) trial is the only large, double‐blind, placebo‐controlled trial of dual antiplatelet therapy (DAPT) versus aspirin in patients with peripheral artery disease (PAD) after lower extremity revascularization (LER).
Marc P. Bonaca, Michael Szarek, E. Sebastian Debus, Mark R. Nehler, Manesh R. Patel, Sonia S. Anand, Eva Muehlhofer, Scott D. Berkowitz, Lloyd P. Haskell, Rupert M. Bauersachs   +9 more
wiley   +1 more source

Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors

New England Journal of Medicine, 2019
Background Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for reversal of factor Xa inhibitors. Methods We evaluated 352 patients who had acute major bleeding within 18 hours after administration of a factor Xa ...
S. Connolly, M. Crowther, J. Eikelboom, M. Gibson, J. Curnutte, J. Lawrence, Patrick Yue, M. Bronson, Genmin Lu, P. Conley, P. Verhamme, Jeannot Schmidt, S. Middeldorp, A. Cohen, J. Beyer-Westendorf, P. Albaladéjo, J. López-Sendón, A. Demchuk, D. Pallin, M. Concha, S. Goodman, J. Leeds, Sonia Souza, D. Siegal, E. Zotova, Brandi Meeks, S. Ahmad, J. Nakamya, T. Milling   +28 more
semanticscholar   +1 more source

Oral Direct Factor Xa Inhibitors [PDF]

Circulation Research, 2012
Vitamin K antagonists, such as warfarin, have been the mainstay of oral anticoagulation for many decades. Although effective, warfarin has numerous limitations, including a variable dose requirement from patient to patient because of differences in dietary vitamin K intake, common genetic polymorphisms, and multiple drug interactions that affect its ...
Jeffrey I. Weitz, Calvin H. Yeh, James C. Fredenburgh   +2 more
openaire   +2 more sources

Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.

New England Journal of Medicine, 2016
BACKGROUND Andexanet alfa (andexanet) is a recombinant modified human factor Xa decoy protein that has been shown to reverse the inhibition of factor Xa in healthy volunteers. METHODS In this multicenter, prospective, open-label, single-group study, we
Stuart J Connolly, T. Milling, J. Eikelboom, C. Michael, Gibson, J. Curnutte, A. Gold, Michele D. Bronson, Genmin Lu, P. Conley, P. Verhamme, Jeannot Schmidt, S. Middeldorp, Alexander T Cohen, J. Beyer-Westendorf, P. Albaladéjo, J. López-Sendón, S. Goodman, J. Leeds, Brian L. Wiens, Deborah M. Siegal, E. Zotova, Brandi Meeks, J. Nakamya, W. Lim, M. Crowther   +25 more
semanticscholar   +1 more source

Application of a microdosed cocktail of 3 oral factor Xa inhibitors to study drug–drug interactions with different perpetrator drugs

British Journal of Clinical Pharmacology, 2020
Using 3 different perpetrators the impact of voriconazole, cobicistat and rifampicin (single dose), we evaluated the suitability of a microdose cocktail of factor Xa inhibitors (FXaI; rivaroxaban, apixaban and edoxaban; 100 μg in total) to study drug ...
G. Mikus, K. Foerster, Marlene Schaumaeker, M. Lehmann, J. Burhenne, W. Haefeli   +5 more
semanticscholar   +1 more source

Determining electronic properties from L-edge X-ray absorption spectra of transition metal compounds with artificial neural networks [PDF]

Phys. Rev. B 103, 045140 (2021), 2020
X-ray absorption spectroscopy at the L-edge probes transitions of 2p-electrons into unoccupied d-states. Applied to transition metal atoms, this experimental technique can provide valuable information about the electronic structure of d-states. However, multiplet effects, spin-orbit coupling, a large number of possible transitions can cause a rather ...
arxiv   +1 more source

Factor Xa Inhibitors [PDF]

, 2016
Factor Xa represents an attractive target for antithrombotic drugs as blockade of factor Xa permits inhibition of both the extrinsic and intrinsic coagulation pathways. Several factor Xa inhibitors, such as rivaroxaban, apixaban and edoxaban, have been approved for certain conditions, and are also in clinical development for other indications.
Gregory Y.H. Lip, Eduard Shantsila
openaire   +2 more sources